Lead-DossierGelandet01:21

BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for HCPs | Safety Info

braf-metastatic-nsclc-hcp-rx.com · Entdeckt vor 1 Std.

Heißer LeadOther

Zusammenfassung

See safety information of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib), a combination treatment for adults with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation.

Zielgruppe: General
Kategorie: Other
Land: Unknown
Status: Live

Tech-Stack

React CloudflareHosting: Cloudflare